Circulating level of macrophage colony-stimulating factor can be predictive for human in vitro fertilization outcome.
OBJECTIVE
To evaluate the level of macrophage colony-stimulating factor (M-CSF) in serum in response to ovarian stimulation (group 1) in low-response (n = 26), moderate-response (n = 40), and high-response (n = 29) patients and to compare its changes (n = 23, group 2) throughout the menstrual cycle between pregnant and nonpregnant patients.


METHODS
Randomized controlled trial.


METHODS
University IVF program.


METHODS
Ninety-five women undergoing IVF.


METHODS
Serum and FF collection from 95 women.


METHODS
The M-CSF concentration was determined by ELISA.


RESULTS
The M-CSF levels in FF were higher than in serum. The M-CSF levels in serum increased from low-, through moderate-, to high-response patients; pregnancy rates were 11.5%, 22.5%, and 51.7%, respectively. Levels of M-CSF in serum increased throughout stimulation until the day of oocyte retrieval and decreased until ET. During the postretrieval days, from the day of ET, through implantation, to the day of confirmation of pregnancy, the M-CSF levels of those patients who became pregnant (n = 13) increased significantly and reached their highest level. After implantation the M-CSF level decreased slightly and reached a plateau during gestation.


CONCLUSIONS
Macrophage colony-stimulating factor is involved in follicle development and ovulation and could be an additional predictor for IVF outcome.
Salmassi
Ali
A
Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Mettler
Liselotte
L
Jonat
Walter
W
Buck
Sybille
S
Koch
Kerstin
K
Schmutzler
Andreas G
AG
D000328:Adult; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D010064:Embryo Implantation; D004624:Embryo Transfer; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use*; D015571:Follicular Fluid / Q000378:metabolism*; D005865:Gestational Age; D006801:Humans; D007246:Infertility / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood / Q000378:metabolism*; D008297:Male; D008597:Menstrual Cycle / Q000187:drug effects / Q000378:metabolism; D054315:Oocyte Retrieval; D010060:Ovulation / Q000187:drug effects* / Q000378:metabolism; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; D016173:Macrophage Colony-Stimulating Factor